These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29998522)

  • 1. Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination.
    Kåberg M; Navér G; Hammarberg A; Weiland O
    J Viral Hepat; 2018 Dec; 25(12):1452-1461. PubMed ID: 29998522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange - evaluated with liver elasticity.
    Kåberg M; Edgren E; Hammarberg A; Weiland O
    Scand J Gastroenterol; 2019 Mar; 54(3):319-327. PubMed ID: 30907178
    [No Abstract]   [Full Text] [Related]  

  • 4. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era.
    Gahrton C; Navér G; Warnqvist A; Dalgard O; Aleman S; Kåberg M
    Int J Drug Policy; 2024 Jun; 128():104433. PubMed ID: 38703622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
    Scott N; Sacks-Davis R; Pedrana A; Doyle J; Thompson A; Hellard M
    J Viral Hepat; 2018 Dec; 25(12):1472-1480. PubMed ID: 30047625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant decrease in injection risk behaviours among participants in a needle exchange programme.
    Kåberg M; Karlsson N; Discacciati A; Widgren K; Weiland O; Ekström AM; Hammarberg A
    Infect Dis (Lond); 2020 May; 52(5):336-346. PubMed ID: 32072841
    [No Abstract]   [Full Text] [Related]  

  • 8. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
    Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
    Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden.
    Lindqvist K; Thorin Z; Kåberg M
    Harm Reduct J; 2023 Jun; 20(1):72. PubMed ID: 37308951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden.
    Kågström E; Lannergård A; El Khosht J; Lörelius P; Månflod J; Strömdahl S
    Harm Reduct J; 2023 Jun; 20(1):77. PubMed ID: 37328868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study.
    Zhu L; Thompson WW; Hagan L; Randall LM; Rudolph AE; Young AM; Havens JR; Salomon JA; Linas BP
    Int J Drug Policy; 2024 Aug; 130():104539. PubMed ID: 39033645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    Schulkind J; Stephens B; Ahmad F; Johnston L; Hutchinson S; Thain D; Ward Z; Vickerman P; Hickman M; Dillon JF
    J Viral Hepat; 2019 May; 26(5):519-528. PubMed ID: 30422370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.